Group 1 - The core viewpoint of the articles highlights that Chengdu Tongde Pharmaceutical Co., Ltd. continues production during the Spring Festival to ensure the supply of essential medicines, specifically the injection of pantoprazole sodium, which is in high demand due to its inclusion in the national centralized procurement list [1][2] - The company operates a fully automated production line, which includes automatic material preparation, cleaning, and filling processes, allowing for efficient production with minimal personnel [1] - Chengdu Tongde has established itself as a leader in the CDMO (Contract Development and Manufacturing Organization) sector in China, particularly in the injectable CDMO field, with over 300 service projects implemented and more than 100 successfully transitioned to market [2]

Core Viewpoint - The company, Asia-Pacific Pharmaceutical (002370.SZ), has participated in the continuation procurement organized by the National Organization for Drug Procurement, with 13 products, including injectable Cefmetazole Sodium and Febuxostat tablets, proposed for selection in the continuation procurement process [1] Group 1: Procurement Details - The continuation procurement involves products from the first to eighth batches of the national organized procurement agreements that have expired [1] - The agreed procurement volume for each product will be based on the demand reported by medical institutions, with the selection price gradient determining the volume ratio [1] Group 2: Market Impact - Medical institutions will prioritize the use of the selected drugs from this continuation procurement during the procurement period, ensuring the completion of the agreed procurement volume [1] - If the company signs procurement contracts and implements them, it will further expand the sales of related products, enhance market share, and improve brand influence, positively impacting future operating performance [1]